These changes increase the expression of positive AKT regulator mTORC2 while reducing the expression of negative AKT regulator PHLPP2, activating the AKT pathway and promoting cell proliferation in endometrial carcinoma [105]. Here, AKT1 is linked to endometrial carcinoma.